tirzepatide cardiovascular outcomes trial In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT results: https://nej.md/4qd5rLx Effects of Tirzepatide in Type
Description
The Food and Drug Administration (FDA) reports that 5% of semaglutide users suffer from constipation
Another common error is storing the pen uncapped or with the needle attached after injection
Weir TL, Majumder M, Glastras SJ
Ideal candidates Microdosing isnt for everyone
Keeping a journal of when symptoms occur, their severity, and any possible triggers can be helpful
Platforms like MeAgain centralize shot reminders, injection-site logging, protein goals, water tracking, and symptom notes
